Please find attached herewith transcript of Earnings call held on 31 July, 2026.

August 7, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Transcript of Earnings Call PursuanttotheRegulation30(6)readwithPartAofScheduleIIIoftheSEBI(ListingObligationsand Disclosure Requirements), Regulations 2015, the transcript of Earnings Call held on Friday, July 31, 2026 for the first quarter ended June 30, 2026 is available on website of the Company at: https://alivus.b-cdn.net/alivus_pdfs/investors/financials/reports_presentation/Alivus-Earnings- Jul31-2026.pdf The said transcript is also attached. Request you to kindly take the same on record. Thanking you Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office: Registered Office: Technopolis Knowledge Park, A wing, Office No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumbai – 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com “Alivus Life Sciences Limited Q1 FY '27 Conference Call” July 31, 2026 MANAGEMENT: DR. YASIR RAWJEE – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER – ALIVUS LIFE SCIENCES LIMITED MR. TUSHAR MISTRY – CHIEF FINANCIAL OFFICER – ALIVUS LIFE SCIENCES LIMITED MS. SOUMI RAO – SENIOR GENERAL MANAGER – ALIVUS LIFE SCIENCES LIMITED Alivus Life Sciences Limited July 31, 2026 Moderator: Ladies and gentlemen, good morning, and welcome to the Alivus Life Sciences Limited Q1 FY '27 Conference Call. As a reminder, all participant lines will remain in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal the operator by pressing star, then zero on your touchtone telephone. Please note that this conference is being recorded. I will now hand the conference over to Ms. Soumi Rao, Senior General Manager of Alivus Life Sciences Limited for opening remarks. Thank you, and over to you. Soumi Rao: Good morning, everyone. I welcome you all to the earnings call of Alivus Life Sciences Limited for the quarter ended June 30, 2026. From Alivus Life Sciences Limited, we have with us Dr. Yasir Rawjee, our MD and CEO; and Mr. Tushar Mistry, our CFO. Our Board has approved the results for the quarter ended June 30, 2026. We have released it to the stock exchanges and updated it on the website. Please note that the recording and transcript of this call will be available on the website of the company. Now I'd like to draw your attention to the fact that some of the information shared as part of this call, especially information with respect to our plans and strategies may contain certain forward-looking statements that involve risks and uncertainties. These statements are based on current expectations, forecasts and assumptions that are subject to risks and which could cause actual results to differ materially from these statements depending upon the economic conditions, government policies and other incidental factors. Such statements should not be regarded by recipients as a substitute of their own judgment. The company undertakes no obligation to update or revise any forward-looking statements. Our actual results may differ materially from those expressed in or implied by these forward-looking statements. With that, I invite Dr. Yasir Rawjee to say a few words. Thank you, and over to you, Dr. Rawjee. Yasir Rawjee: Thank you, Soumi. Good morning, everyone, and welcome to our Q1 FY '27 earnings call. We are pleased to begin the first quarter on a positive note marked by healthy revenue growth, improving profitability and continuing momentum across our markets. We reported revenues of INR640 crores, which is a 6.4% year-on-year growth during the quarter. Our performance this quarter was particularly encouraging as it delivered despite a significant decline in the GPL business, reflecting the growing strength of our broader portfolio and the resilience of our business model. Our non-GPL business delivered strong growth of 26.5% year-on-year, driven by successful new product launches and strong demand across all geographies. The momentum we have built in recent quarters continues to strengthen with recently launched products continuing to gain scale across markets. So this has provided greater diversification to our revenue base and created a platform for sustainable growth going forward, giving us confidence in the sustainability of this momentum. Page 2 of 12 Alivus Life Sciences Limited July 31, 2026 GPL has been muted as a result of inventory rationalization. And so if you recall, Q4 was pretty strong, and we saw a dip in Q1, a decline of 52.6% year-on-year. However, the strong execution across the non-GPL portfolio helped us to offset this impact, underscoring the benefits of a broader and increasingly diversified growth engine. While growth in the GPL business is expected to remain flattish in FY '27, the business has been historically weighted towards the second half of the year and we expect a similar trend to play out this year, resulting in a stronger H2 performance. At the same time, we expect the healthy growth momentum in the non-GPL business to continue, supported by a robust product pipeline, recent launches and sustained demand across all markets. This provides us confidence in our ability to deliver growth despite the near-term weakness in the GPL business. Overall, the underlying strength of the API business remains intact. Geographically, we saw broad-based growth across all markets during the quarter, highlighting the strength of the diversified business. On the profitability front, a favourable product mix and newer launches helped improve gross margins to 60.2%, an increase in 510 basis points year-on-year. Enhanced operational efficiencies and forex gains also supported 650 basis points Y-o-Y improvement in EBITDA margins to 36.6%. These margins reflect the quality of our growth and disciplined execution. Our CDMO business recorded 3.8% Y-o-Y growth during the first quarter. Given the inherently lumpy nature of the CDMO business, the performance does vary from quarter-to-quarter. We've seen that before. However, we can expect the segment to gain momentum in the second half of the year, supported by contributions from newly added projects. On the capex front, Solapur continues to progress as planned. There's a little bit of a delay, but it's going to be operational in early Q3 of FY '27. Construction at Taloja, the R&D center has begun in earnest, and it will happen on schedule. The pipeline remains robust, with 617 DMF and CEP filings globally as on June 30. Our high-potent API portfolio continues to advance with 29 products in the active grid, representing a total addressable market of $82 billion. Of these 13 products have been validated, 7 are in advanced stages of development and the remaining 9 products are progressing through lab development stages. So while we remain watchful of the evolving geopolitical and demand environment, the strength of our business fundamentals gives us confidence in our growth outlook. We are guiding for revenue growth of 10% to 12% in FY '27 with growth skewed towards H2 FY '27. We also remain confident of sustaining EBITDA margins in the 30% to 32% range. So with this, I now turn the floor to our CFO, Mr. Tushar Mistry, who will walk you through our financial performance for the quarter in depth. Page 3 of 12 Alivus Life Sciences Limited July 31, 2026 Tushar Mistry: Thank you, Dr. Yasir. Goo [Showing first 8,000 characters — download PDF for full document]